Boston Scientific Lands NTAP Status For Single-Use Scope

US Medicare’s designation of Boston Scientific’s single-use duodenoscope aims to reduce infections from a popular procedure to treat pancreatic and biliary conditions.

BOSTON SCIENTIFIC.
• Source: Alamy

The US Centers for Medicare & Medicaid Services (CMS) has granted the Exalt-D single-use duodenoscope from Boston Scientific Corp. new technology add-on payment (NTAP) as part of the agency’s fiscal year 2022 hospital inpatient prospective payment system.

As of 1 October, CSM will provide hospitals with additional device reimbursement when the Exalt-D is used in hospital inpatient settings. The agency previously granted the device transitional passthrough payment...

More from Regulation

More from Policy & Regulation